𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Protein kinase inhibitors: novel tools in cancer therapy

✍ Scribed by D. Marmé

Publisher
Springer
Year
2004
Tongue
German
Weight
297 KB
Volume
43
Category
Article
ISSN
0340-2592

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy with irinotecan and
Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma
✍ Thomas C. Chen; Susan Su; David Fry; Leonard Liebes 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 853 KB

The topoisomerase-I inhibitor irinotecan (CPT-11) is currently used in Phase I/II trials for the treatment of patients with recurrent malignant gliomas. Protein kinase C (PKC) inhibitors such as high-dose tamoxifen and hypericin also have been used in the treatment of malignant gliomas. The current

Development of anaplastic lymphoma kinas
Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy
✍ Rongshi Li; Stephan W. Morris 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 433 KB

## Abstract Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) involved in the genesis of several human cancers; indeed, ALK was initially identified in constitutively activated and oncogenic fusion forms—the most common being nucleophosmin (NPM)‐ALK—in a non‐Hodgkin's lymphoma (N

The biology of a prostate cancer metasta
The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein
✍ Evan T. Keller; Zheng Fu; Meghan Brennan 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB

Raf kinase inhibitor protein (RKIP) was originally identified as a protein that bound membrane phospholipids and was named phosphatidylethanolamine binding protein-2 (PEBP-2). RKIP was than identified as a protein that bound Raf and blocked its ability to phosphorylate MEK, thus earning its new name